Imagion, a privately owned company based in Germany, was founded in 2000 and operates with approximately 30 employees. The company specializes in media managed services, functioning as an authoring and encoding studio for video-on-demand (VOD) content.
Imagion secured US FDA approval on August 5, 2026, to initiate its MagSense HER2 Imaging Agent Phase 1b/2 clinical trial, marking progress in the US market and strengthening its relationship with Provider Network Solutions. Previously, on September 24, 2025, the company reported strong progress towards a US Investigational New Device (IND) submission that would pave the way for a Phase II breast cancer detection trial, with Imagion chief Bob Proulx stating current cancer imaging tools are "not good enough." Market commentators on September 12, 2025, highlighted Imagion's cancer imaging comeback as it neared the start of a pivotal phase two cancer trial. Earlier, on September 11, 2025, Pitt Street Research indicated Imagion was "undervalued," estimating it sat 75-80% below a target range of 12.3 to 14.9 cents per share and anticipating further upside if its MagSense imaging agent technology advanced to commercialization. Imagion commenced manufacturing for its Phase 2 HER2 clinical trial on September 8, 2025, also initiating a WSU Imaging Optimisation Program to support the planned trial, which was expected to begin towards the end of 2025.
Imagion offers 4 products in the media tech industry. Imagion's product portfolio comprises of media managed services.
Subscribe for full access to Imagion's products in full detail
Imagion's revenues were less than $10M in 2024. Caretta Research has split Imagion's revenue into 4 different product categories, the largest of which is post production services. For full access to Imagion's revenue breakdown subscribe to Caretta Portal.
Subscribe for full access to Imagion's revenue in full detail
Subscribe for full access to Imagion's products in full detail 
